Pipecolic Acid

Pipecolic Acid

SCHEMBL1002076

O=C(O)C1CCCCN1.O=C(O)[C@@H]1CCCCN1

nearest known ligand 0.57

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BLM P54132 3/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
NOS2 P35228 2/20 0.43
DPP4 P27487 2/20 0.43
DPP8 Q6V1X1 1/20 0.43
DPP9 Q86TI2 1/20 0.43
NOS3 P29474 1/20 0.43
NOS1 P29475 1/20 0.43
CYP2D6 P10635 2/20 0.42
LMNA P02545 2/20 0.42
ALOX15 P16050 2/20 0.42
CYP1A2 P05177 2/20 0.42
CYP2C19 P33261 2/20 0.42
THRB P10828 2/20 0.42
TSHR P16473 1/20 0.42
RAB9A P51151 1/20 0.42
PMP22 Q01453 1/20 0.42
ALDH1A1 P00352 1/20 0.40
GRIN2D O15399 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pipecolic Acid SCHEMBL22016 1.00
Pipecolic Acid SCHEMBL40185 1.00
Pipecolic Acid SCHEMBL4758702 1.00 BLM (0.45) BLMMEN1KMT2ANOS2DPP4
Pipecolic Acid SCHEMBL1078450 1.00 BLM (0.45) BLMMEN1KMT2ANOS2DPP4
Pipecolic Acid SCHEMBL58642 1.00
Pipecolic Acid SCHEMBL30552181 1.00
Pipecolic Acid SCHEMBL29479229 1.00
SCHEMBL23997628 0.98 MEN1 (0.43) BLMMEN1KMT2ANOS2DPP4
SCHEMBL6235834 0.98 MEN1 (0.43) BLMMEN1KMT2ANOS2DPP4
SCHEMBL5568760 0.98 MEN1 (0.43) BLMMEN1KMT2ANOS2DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10745382-B2 Compounds useful as immunomodulators BRISTOL-MYERS SQUIBB COMPANY (US) 2020-08-18 US disclosed
EP-3362443-A1 COMPOUNDS USEFUL AS IMMUNOMODULATORS Bristol-Myers Squibb Company (US) 2018-08-22 EP disclosed
EP-3158053-A1 ACCELERATION OF MYCOBACTERIUM GROWTH St. George's Hospital Medical School (GB) 2017-04-26 EP disclosed
US-20170107202-A1 COMPOUNDS USEFUL AS IMMUNOMODULATORS BRISTOL-MYERS SQUIBB COMPANY 2017-04-20 US disclosed
WO-2017066227-A1 COMPOUNDS USEFUL AS IMMUNOMODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2017-04-20 WO disclosed
WO-2015193688-A1 ACCELERATION OF MYCOBACTERIUM GROWTH ST GEORGE'S HOSPITAL MEDICAL SCHOOL (GB) 2015-12-23 WO disclosed
US-7868135-B2 Compositions of lipopeptide antibiotic derivatives and methods of use thereof BIOWEST THERAPEUTICS INC. (CA) 2011-01-11 US disclosed
WO-2008151434-A1 SMALL CATIONIC ANTIMICROBIAL PEPTIDES THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10745382-B2 Compounds useful as immunomodulators CD74, HLA-DRB1, CD47 BLM 549/4885MEN1 1857/4885KMT2A 4121/4885
US-20170107202-A1 COMPOUNDS USEFUL AS IMMUNOMODULATORS CD74, HLA-DRB1, CD47 BLM 549/4885MEN1 1857/4885KMT2A 4121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.